Medicare Enrolled

Dr. Abirami Muthukumaran, M.D

Neurology · Los Angeles, CA
Practice pattern: Remote Monitoring — Significant remote device monitoring activity
Low-engagement
1220 MANNING AVE APT 14, Los Angeles, CA 90024
8182700217
In practice since 2006 (19 years)
NPI: 1619050572 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Muthukumaran from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Muthukumaran? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Muthukumaran

Dr. Abirami Muthukumaran is a neurology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Muthukumaran performed 2,025 Medicare services across 470 unique beneficiaries.

Between the years covered by Open Payments, Dr. Muthukumaran received a total of $5,866 from 32 pharmaceutical and/or device companies across 345 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Muthukumaran is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 21% volume in CA $5,866 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,025
Medicare services
Top 21% in CA for neurology
470
Unique beneficiaries
$33
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~107 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Continuous intraoperative neurophysiology monitoring, remote
Remote monitoring of nerve and brain function during surgery, billed in 15-minute increments.
1,661 $27 $105
Placement of skin electrodes and measurement of stimulated sites on arms and legs
This procedure involves placing skin electrodes and measuring stimulated sites on the arms and legs.
153 $38 $147
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
51 $78 $321
Central motor stimulation test of arms and legs
This procedure involves placing skin electrodes on the body to measure how the central nervous system stimulates the muscles in the arms and legs.
50 $101 $384
Electromyography of arm or leg muscles
A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them.
45 $44 $376
Electromyography of 2 extremities
A test that measures the electrical activity in the muscles of two arms or legs. It helps evaluate nerve and muscle function.
29 $69 $264
Nerve conduction studies, 7-8 tests
A series of 7 to 8 nerve conduction tests to evaluate how well nerves are sending signals to muscles.
19 $54 $608
Central motor stimulation measurement with skin electrodes
Skin electrodes are placed to measure central motor stimulation in the arms.
17 $68 $259
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$5,866
Total received (2018-2024)
Avg $838/year across 7 years
Top 30% in CA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
32
Companies
345
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,768 (98.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$99 (1.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,803
2023
$1,225
2022
$947
2021
$658
2020
$247
2019
$545
2018
$441

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$541
UCB, Inc.
$290
Neurelis, Inc.
$249
PFIZER INC.
$244
EMD Serono, Inc.
$121
ARGENX US, INC.
$79
Biogen, Inc.
$53
Otsuka America Pharmaceutical, Inc.
$48
Amgen Inc.
$35
Novartis Pharmaceuticals Corporation
$33
Lundbeck LLC
$29
SK Life Science, Inc.
$24
MITSUBISHI TANABE PHARMA AMERICA, INC.
$22
Novo Nordisk Inc
$18
LivaNova USA, Inc.
$17
Top 3 companies account for 59.9% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$1,513
UCB, Inc.
$1,215
Biogen, Inc.
$711
EMD Serono, Inc.
$442
Neurelis, Inc.
$322
PFIZER INC.
$284
Biohaven Pharmaceutical Holding Company Ltd.
$166
Allergan, Inc.
$118
Novartis Pharmaceuticals Corporation
$109
MITSUBISHI TANABE PHARMA AMERICA, INC.
$95
Amgen Inc.
$89
Eisai Inc.
$81
ARGENX US, INC.
$79
Allergan Inc.
$66
Greenwich Biosciences, Inc.
$55
LivaNova USA, Inc.
$50
Otsuka America Pharmaceutical, Inc.
$48
Mitsubishi Tanabe Pharma America, Inc.
$46
Acorda Therapeutics, Inc
$42
EISAI INC.
$36
CSL Behring
$35
Sumitomo Pharma America, Inc.
$34
Lundbeck LLC
$29
Teva Pharmaceuticals USA, Inc.
$29
IMPEL PHARMACEUTICALS INC.
$25
SK Life Science, Inc.
$24
Merck Sharp & Dohme Corporation
$24
Abbott Laboratories
$24
Supernus Pharmaceuticals, Inc.
$23
Amylyx Pharmaceuticals, Inc.
$20
Novo Nordisk Inc
$18
Genentech USA, Inc.
$18
Top 3 companies account for 58.6% of all-time payments
Associated products mentioned in payments ›
AMPYRA · APTIOM · Aimovig · Austedo XR · BOTOX · BOTOX - NEUROLOGY · BOTOX THERAPEUTIC · Briviact · COMIRNATY · Epidiolex · Fintepla · Fycompa · Hizentra · INBRIJA · ISENTRESS · Infinity DBS Pulse Generators · KESIMPTA · MAVENCLAD · Mavenclad · NURTEC ODT · OCREVUS · PAXLOVID · QULIPTA · RADICAVA · RELYVRIO · REXULTI · Radicava · Rebif · Rystiggo · TECFIDERA · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · UPLIZNA · VALTOCO · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · Wegovy
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a neurology specialist in Los Angeles?
Compare neurologists in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse neurologists nearby

Geographic Context

Neurologists within 10 mi
538
Per 100K population
5.5
County median income
$87,760
Nearest hospital
RONALD REAGAN UCLA MEDICAL CENTER
0.6 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Muthukumaran is a remote monitoring specialist, with above-average Medicare volume (top 21% in CA), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Muthukumaran experienced with continuous intraoperative neurophysiology monitoring, remote?
Based on Medicare claims data, Dr. Muthukumaran performed 1,661 continuous intraoperative neurophysiology monitoring, remote services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Muthukumaran receive payments from pharmaceutical companies?
Yes. Dr. Muthukumaran received a total of $5,866 from 32 companies across 345 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Muthukumaran's costs compare to other neurologists in Los Angeles?
Dr. Muthukumaran's average Medicare payment per service is $33. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Muthukumaran) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →